Quarterly ResultAug 13, 2026, 04:14 PM
Silo Pharma Q2 Net Loss Narrows to $0.83M; Forms AI Subsidiary
AI Summary
Silo Pharma reported a net loss of $0.83 million for the second quarter of 2026, an improvement from $1.20 million in the same period last year, with diluted EPS improving to $(0.76). However, the net loss for the first half of 2026 increased to $2.48 million. The company also announced the formation of Qwikagentsai Inc. to diversify into AI technology and completed a 1-for-15 reverse stock split in June 2026. Cash and cash equivalents decreased to $3.28 million, and license fee revenue was negligible.
Key Highlights
- Net loss for Q2 2026 was $0.83 million, an improvement from $1.20 million in Q2 2025.
- Diluted EPS for Q2 2026 improved to $(0.76) from $(2.88) in Q2 2025.
- Net loss for H1 2026 increased to $2.48 million from $2.24 million in H1 2025.
- Cash and cash equivalents decreased to $3.28 million from $4.75 million at year-end 2025.
- Formed Qwikagentsai Inc. on April 15, 2026, to diversify into AI technology.
- Effectuated a 1-for-15 reverse stock split on June 2, 2026.
- License fee revenue was $0 for Q2 2026, down from $18,025 in Q2 2025.
- Accumulated deficit reached $21.97 million as of June 30, 2026.
Price Impact
More from SILO